KRAS and colorectal carcinoma: The open-label, randomized, multicenter FIRE-3 trial assigned 592 patients with KRAS exon 2 wild-type metastatic CRC to FOLFIRI plus cetuximab or FOLFIRI plus bevacizumab in first-line treatment.